Patents by Inventor Erika Morizzo

Erika Morizzo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200190217
    Abstract: Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P. aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.
    Type: Application
    Filed: July 17, 2018
    Publication date: June 18, 2020
    Applicant: Ablynx N.V.
    Inventors: Evelyn De Tavernier, Ann Union, Bruno Dombrecht, Guy Hermans, Erika Morizzo
  • Publication number: 20190367597
    Abstract: The present invention relates to amino acid sequences that can bind to serum albumin. In particular, the present invention relates to immunoglobulin single variable domains, and in particular heavy-chain immunoglobulin single variable domains, that can bind to serum albumin. The invention also relates to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise at least one of the immunoglobulin single variable domains binding to serum albumin that are described herein.
    Type: Application
    Filed: January 17, 2018
    Publication date: December 5, 2019
    Applicant: Ablynx N.V.
    Inventors: Stephanie STAELENS, Soren STEFFENSEN, Erika MORIZZO, An CERDOBBEL
  • Publication number: 20190367598
    Abstract: The present invention relates to amino acid sequences that can bind to serum albumin. In particular, the present invention relates to immunoglobulin single variable domains, and in particular heavy-chain immunoglobulin single variable domains, that can bind to serum albumin. The invention also relates to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise at least one of the immunoglobulin single variable domains binding to serum albumin that are described herein.
    Type: Application
    Filed: January 17, 2018
    Publication date: December 5, 2019
    Applicant: Ablynx N.V.
    Inventors: Stephanie STAELENS, Soren STEFFENSEN, Erika MORIZZO, An CERDOBBEL
  • Publication number: 20190367596
    Abstract: The present invention relates to amino acid sequences that can bind to serum albumin. In particular, the present invention relates to immunoglobulin single variable domains, and in particular heavy-chain immunoglobulin single variable domains, that can bind to serum albumin. The invention also relates to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise at least one of the immunoglobulin single variable domains binding to serum albumin that are described herein.
    Type: Application
    Filed: December 7, 2017
    Publication date: December 5, 2019
    Applicant: Ablynx N.V.
    Inventors: Stephanie Staelens, Soren Steffensen, Erika Morizzo, Raf Ponsaerts, Ingrid Ottevaere, An Cerdobbel
  • Publication number: 20190055322
    Abstract: Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P. aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.
    Type: Application
    Filed: July 17, 2018
    Publication date: February 21, 2019
    Applicant: Ablynx N.V.
    Inventors: Evelyn De Tavernier, Ann Union, Bruno Dombrecht, Guy Hermans, Erika Morizzo
  • Patent number: 10072098
    Abstract: Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: September 11, 2018
    Assignee: Ablynx N.V.
    Inventors: Evelyn De Tavernier, Ann Union, Bruno Dombrecht, Guy Hermans, Erika Morizzo
  • Publication number: 20150044215
    Abstract: Polypeptides are provided that are capable of significantly inhibiting andor neutralizing P aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.
    Type: Application
    Filed: March 4, 2013
    Publication date: February 12, 2015
    Applicant: Ablynx N.V.
    Inventors: Evelyn De Tavernier, Ann Union, Bruno Dombrecht, Guy Hermans, Erika Morizzo
  • Publication number: 20130109842
    Abstract: The present invention relates to amino acid sequences that are directed against the p19 subunit of IL-23; as well as protein, constructs and compounds comprising the same; and also nucleic acids encoding the same.
    Type: Application
    Filed: April 28, 2011
    Publication date: May 2, 2013
    Applicant: Ablynx N.V.
    Inventors: Veronique De Brabandere, Marc Jozef Lauwereys, Erika Morizzo, Heidi Rommelaere, Ann Union, Gert Verheyden
  • Publication number: 20120264917
    Abstract: Biparatopic protein constructs that are directed against IL-23, and in particular against the p19 subunit of IL-23. The constructs comprise at least a first binding domain or binding unit directed against a first defined epitope on p19 and at least a second binding domain or binding unit directed against a second defined epitope on p19 (or the p19/p40 interface). The binding domains or binding units may in particular be a domain antibody, a single domain antibody, a dAb or a Nanobody®. The constructs and pharmaceutical compositions comprising the same can be used for the prevention and/or treatment of diseases and disorders associated with IL-23 or IL-23 mediated signaling, such as inflammation and inflammatory disorders such as colitis, Crohn's disease and IBD, infectious diseases, psoriasis, cancer, autoimmune diseases, sarcoidosis, transplant rejection, cystic Fibrosis, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, viral infection, and common variable immunodeficiency.
    Type: Application
    Filed: May 27, 2010
    Publication date: October 18, 2012
    Applicant: Ablynx N.V.
    Inventors: Michael John Scott Saunders, Christophe Blanchetot, Carlo Boutton, Heidi Rommelaere, Johannes Joseph Wilhelmus De Haard, Veronique De Brabandere, Marc Jozef Lauwereys, Erika Morizzo, Ann Union, Gert Verheyden